Browse the evidence

Semaglutide 2.4 mg weekly significantly improves symptoms, functional capacity, and reduces systemic inflammation in obese patients with heart failure with preserved ejection fraction (HFpEF).

If you have heart failure with preserved ejection fraction and are obese, ask your doctor about semaglutide. It is a once-weekly injection that has been shown to significantly improve your heart failure symptoms, exercise capacity, and reduce inflammation. While it may cause temporary stomach issues, the benefits for your heart and weight are substantial.

Genetic variation in the NBEA gene predicts weight loss response to GLP-1 receptor agonists (GLP-1RAs), with specific NBEA scores identifying individuals likely to be highly responsive or non-responsive to treatment.

If you are prescribed a GLP-1RA like semaglutide or liraglutide, ask your doctor about genetic testing for the NBEA gene. This test can predict whether you are likely to lose significant weight (top 20% responders) or not respond at all. This helps avoid wasting time and money on medications that are unlikely to work for your specific biology, allowing for a more personalized and effective obesity treatment plan.

Achieving ≥20–25% early postoperative weight loss (EWL) within the first 3–6 months after bariatric surgery strongly predicts sustained long-term weight loss (≥50% EWL) and metabolic remission.

If you had bariatric surgery, your weight loss in the first 3-6 months is a major predictor of your long-term success. Aim for at least 20-25% excess weight loss in this window. If you are slower, do not give up; this is a signal for your medical team to intensify support (nutrition, behavioral therapy, or medication) to help you catch up.

Semaglutide 2.4 mg is recommended for secondary prevention of cardiovascular events in individuals with BMI ≥27 kg/m² without diabetes but with established cardiovascular disease.

If you have established heart disease, are overweight (BMI ≥27), and do not have diabetes, ask your doctor about semaglutide 2.4 mg. This medication is recommended to help prevent future heart attacks, strokes, and cardiovascular death.

Bariatric surgery (VSG and RYGB) improves metabolic health and promotes weight loss by altering gut microbiota to increase the production of specific metabolites (licoricidin and butyrate) that activate thermogenesis in adipose tissue.

Bariatric surgery's success is largely due to how it changes your gut bacteria to burn more fat, not just by making you eat less. This suggests that targeting gut health and metabolism could be key to treating obesity, potentially leading to new non-surgical treatments.

Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.

To leverage the gut-brain axis for weight management, reduce your daily caloric intake by 20-40% while ensuring you get adequate nutrients. This specific type of dietary restriction has been shown to improve gut bacteria diversity, reduce inflammation, and boost satiety hormones, making it easier to maintain energy balance.

Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.

Obesity is linked to changes in gut bacteria that disrupt signals for hunger and fullness. These changes include lower bacterial diversity and reduced production of satiety hormones. Understanding this link highlights why dietary changes can help reset these signals.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors reduce cardiovascular events and improve liver histology in MASLD patients, particularly those with type 2 diabetes or obesity.

If you have MASLD and diabetes or obesity, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT2 inhibitors. These drugs not only help control blood sugar and weight but also significantly lower the risk of heart attacks and strokes, and may improve liver health. They are safe for use in MASLD patients within their approved indications.

Excess adiposity (BMI ≥30) is a causal risk factor for gastrointestinal cancers, increasing incidence and mortality through endocrine, inflammatory, and mechanical pathways.

Maintain a healthy weight to reduce your risk of gastrointestinal cancers. If you are overweight, consult your doctor about structured weight loss strategies, as obesity increases cancer risk and complicates surgical outcomes.

Semaglutide significantly reduces the risk of atrial fibrillation (AF) and sinus node dysfunction in patients with overweight or obesity.

If you have overweight or obesity and are concerned about heart rhythm issues like atrial fibrillation, semaglutide therapy (up to 2.4 mg) has been shown in large studies to significantly lower that risk. This benefit appears particularly strong in patients over 60 and those treated for more than a year.

Semaglutide significantly reduces the risk of acute myocardial infarction and angina pectoris in patients with overweight or obesity, with greater efficacy observed in patients over 60 years and those treated for more than 52 weeks.

For patients with overweight or obesity, semaglutide (up to 2.4 mg) significantly lowers the risk of heart attacks and angina. This benefit is particularly pronounced in patients over 60 years old and those who maintain treatment for more than one year, suggesting that long-term adherence is key to maximizing cardiovascular protection.

Akkermansia muciniphila supplementation in obese humans leads to greater weight loss and decreased plasma LPS levels compared to placebo, suggesting a direct microbiome-based therapy for obesity.

Akkermansia muciniphila is a specific gut bacterium that has shown promise in clinical trials for aiding weight loss in obese individuals. While not yet a formal recommendation, consuming foods that support this bacterium (like polyphenols) may be beneficial. Consult a healthcare provider before considering specific supplementation.

GLP-1 receptor agonists (GLP-1RAs) improve lipid profiles (lowering triglycerides, LDL-C, and total cholesterol, and raising HDL-C) in patients with type 2 diabetes and obesity, but these lipid-lowering effects are likely a modest contributor to their overall cardiovascular benefit.

GLP-1 medications like semaglutide and tirzepatide do improve your cholesterol and triglyceride levels, often significantly. However, their main heart-protective power comes from helping you lose weight, control blood sugar, and reduce inflammation, rather than just fixing your lipid numbers. You should still monitor your lipids, but don't expect these drugs to replace statins solely for lipid management.

Semaglutide reduces cardiovascular risk (MACE) and improves lipid profiles and blood pressure in patients with type 2 diabetes, independent of weight loss.

For patients with Type 2 Diabetes and high cardiovascular risk, semaglutide offers significant protection against major adverse cardiovascular events (heart attack, stroke, cardiovascular death) and slows kidney disease progression. It also modestly lowers blood pressure and improves lipid profiles through mechanisms independent of weight loss.

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) significantly improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, though they carry a risk of lean mass loss.

If you have HFpEF and obesity, GLP-1/GIP medications like semaglutide or tirzepatide can significantly improve your heart health, symptoms, and quality of life. To counteract potential muscle loss, you must combine these medications with resistance training and high protein intake. Discuss these options with your cardiologist, as they are increasingly recognized as effective treatments for this specific heart condition.

Tirzepatide reduces liver fat content and visceral adipose tissue in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about liver health, tirzepatide not only helps control blood sugar and weight but also significantly reduces liver fat, which is beneficial for overall metabolic health.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and renal events compared to placebo, demonstrating cardiovascular and renal benefits beyond glycemic control.

For patients with Type 2 Diabetes, GLP-1 medications offer protection for the heart and kidneys, reducing the risk of major cardiovascular events and kidney disease progression, independent of their weight loss effects.

Resmetirom (80-100 mg daily) significantly improves MASH resolution and fibrosis regression in patients with F2-F3 fibrosis compared to placebo.

If you have moderate-to-advanced liver scarring from MASH, resmetirom is the first approved drug to help reverse it. Take 80mg or 100mg daily. Expect possible mild stomach issues, but serious risks are low. This targets the root hormonal imbalance driving liver fat.

GLP-1 receptor agonists (e.g., Semaglutide) improve MASH indirectly through weight loss and improved insulin resistance, as the liver lacks direct GLP-1 receptors.

GLP-1 drugs like Semaglutide help MASH by making you lose weight and improving insulin sensitivity, not by acting directly on the liver. They are approved for obesity and diabetes and show strong benefits for liver health through these indirect pathways.

GLP-1 receptor agonists (specifically liraglutide 3 mg/day) produce significant weight loss (8% mean reduction) and improve cardiovascular risk factors in obese and type 2 diabetic patients, though they carry a high discontinuation rate due to gastrointestinal side effects.

Liraglutide 3 mg daily is a highly effective pharmacological tool for weight loss, particularly for those with obesity or type 2 diabetes. It works by mimicking a gut hormone to increase satiety and slow digestion. While effective, it requires daily injections and careful dose titration to manage nausea. It is not a magic bullet; lifestyle changes are still required, and the high side-effect profile means it is not suitable for everyone.

Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training does not impair skeletal muscle hypertrophy gains compared to placebo.

If you are doing resistance training and need pain relief, 300mg of PEA daily (split into two doses) will not hurt your muscle growth. It is a safe alternative to NSAIDs like ibuprofen, which can sometimes blunt strength gains. Take one capsule before your workout and one before bed.

Metformin is effective for preventing type 2 diabetes in prediabetic women, with efficacy varying by menopausal stage and hormonal status.

If you are a woman with prediabetes, metformin is a proven tool to prevent type 2 diabetes, but its effectiveness depends heavily on your menopausal status. It works best for premenopausal women and those who have gone through natural menopause, rather than those who have had their ovaries removed. While lifestyle changes are the first step, metformin is particularly valuable for high-risk individuals (younger, higher BMI, history of gestational diabetes) where lifestyle changes alone may not be enough. Be prepared for potential gastrointestinal side effects, which often improve over time.

Tirzepatide improves insulin sensitivity by 65.7%, a significantly greater improvement than the 37.5% observed with semaglutide.

Tirzepatide works differently than semaglutide by targeting both GLP-1 and GIP receptors, which leads to a much larger improvement in how your body uses insulin (65.7% vs 37.5%). This enhanced insulin sensitivity contributes to better blood sugar control and greater weight loss.

Phentermine-Topiramate produces moderate weight loss (7.87-8.45%) and improves cardiometabolic risk factors, but carries higher risks of neuropsychiatric and cardiovascular side effects compared to GLP-1RAs.

Phentermine-Topiramate is an oral medication that produces moderate weight loss (approx 8%). It is less effective than GLP-1RAs and carries higher risks of side effects like anxiety, paresthesia, and cardiovascular issues. It is not recommended for patients with existing heart disease.